---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-26-002796"
form_type: "8-K"
ticker: "TEVA"
cik: "0000818686"
company_name: "TEVA PHARMACEUTICAL INDUSTRIES LTD"
filed_at: "2026-04-29T23:59:59+00:00"
generated_at: "2026-05-15T02:35:46.535500+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Teva Q1 revenues $4.0B (+2% YoY); AUSTEDO up 41%; to acquire Emalex for $700M cash

## Summary
- Q1 GAAP diluted EPS $0.31; Non-GAAP diluted EPS $0.53; revenues $3,982M (+2% USD, -3% LC).
- Key innovative brands: AUSTEDO $578M (+41% YoY), AJOVY $196M (+35%), UZEDY $63M (+62%).
- Generics down 16% LC due to lenalidomide competition and Japan BV divestiture.
- Acquired Emalex Biosciences for $700M upfront + up to $200M milestones + royalties; ecopipam (Tourette) NDA-ready; close expected Q3 2026.
- 2026 outlook maintained; Non-GAAP diluted EPS $1.91-$2.11 (stand-alone $2.57-$2.77).

## SEC filing metadata
- accession: 0001171843-26-002796
- form_type: 8-K
- ticker: TEVA
- cik: 0000818686
- company_name: TEVA PHARMACEUTICAL INDUSTRIES LTD
- filed_at: 2026-04-29T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/818686/000117184326002796/0001171843-26-002796-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/818686/000117184326002796/f8k_042926.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-26-002796
- JSON: https://secwatch.observer/filing/0001171843-26-002796.json
- Plain text: https://secwatch.observer/filing/0001171843-26-002796.txt

## Key facts
- Earnings Releases
  TEVA PHARMACEUTICAL INDUSTRIES LTD reported quarter ended March 31, 2026 results: revenue Revenues of $4.0 billion, EPS GAAP diluted EPS of $0.31. Guidance reaffirmed.
  - Period: quarter ended March 31, 2026
  - Revenue: Revenues of $4.0 billion
  - EPS: GAAP diluted EPS of $0.31
  - Guidance: reaffirmed
  - Result: reported results
  source text: Q1 2026 Highlights: Revenues of $4.0 billion GAAP diluted EPS of $0.31 Non-GAAP diluted EPS of $0.53 Cash flow used in operating activities of $40 million Free cash flow of $188 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/818686/000117184326002796/0001171843-26-002796-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.